June 2022 "June 15, 2022 06:30 AM EDT - In 2016, Abbie Celniker was promoted to partner at Third Rock Ventures as the firm raised just over $600 million for its fourth fund. Since then, Celniker has helped usher in an additional fund and headed a few startups as interim CEO. Coming on its 15th year, Third Rock Ventures announced its sixth fund today — and largest one by far — at a whopping $1.1 billion. Adding it all up, Third Rock has raised $3.8 billion since its inception. That money has gone to some 60 biotechs, much of it as early funding." Read more at the source #DrGPCR #GPCR #IndustryNews

Join us for the first virtual cafe talk to hear about the amazing work that Dr. Brian Arey is doing. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

September 2022 "Morphine, the most widely used analgesic, relieves severe pain by activating the μ-opioid receptor (MOR), whereas naloxone, with only slight structural changes compared to morphine, exhibits inhibitory effect, and is used to treat opioid abuse. The mechanism by which the MOR distinguishes between the two is unclear. Molecular dynamics (MD) simulations on a 1-μs time scale and metadynamics-enhanced conformational sampling are used here to determine the different interactions of these two ligands with MOR: morphine adjusted its pose by continuously flipping deeper into the pocket, whereas naloxone failed to penetrate deeper because its allyl group conflicts with several residues of MOR. The endogenous peptide ligand endomorphin-1 (EM-1) underwent almost no significant conformational changes during the MD simulations. To validate these processes, we employed GIRK4S143T, a MOR-activated Gβγ-protein effector, in combination with mutagenesis and electrophysiological recordings. We verified the role of some key residues in the dynamic recognition of naloxone and morphine and identified the key residue I322, which leads to differential recognition of morphine and naloxone while assisting EM-1 in activating MOR. Reducing the side chain size of I322 (MORI322A) transformed naloxone from an inhibitor directly into an agonist of MOR, and I322A also significantly attenuated the potency of MOR on EM-1, confirming that binding deep in the pocket is critical for the agonistic effect of MOR. This finding reveals a dynamic mechanism for the response of MOR to different ligands and provides a basis for the discovery of new ligands for MOR at the atomic level." Read more at the source #DrGPCR #GPCR #IndustryNews

Mark your calendar for September and October 2024. Dr. Maria Waldhoer, JoAnn Trejo, and Anne Marie Quinn. Did you watch Episode #150 of the Dr. Dr. GPCR Matchmaking Mark Schmeizl, our Chief Matchmaker, can help you find your perfect match if you want Contact Mark today to get started. Dr.

Hello Dr. GPCR ecosystem members!  also the hiring manager for their open Principal Scientist, In Vitro Pharmacology role posted in the Dr Mark:  “Beth, why did you decide to join Crinetics?” Mark:  “Are there particular assay types of interest?” By: Mark Schmeizl Chief Matchmaker at Dr. GPCR

Mark your calendars for September and October 2024! We are excited to announce that Dr. Dr. GPCR Podcast Exciting news! Episode 152 with Dr. Our most recent episode features our very own Dr. GPCR Board. Tune in and enjoy! Dr. GPCR Matchmaking Meet Mark Schmeizl, our Chief Matchmaker. Mark your calendar for the GPCRs as Therapeutic Targets symposium on October 11th, 2024.

Join our upcoming Dr. GPCR University hands-on workshop with Dr.  The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Dr. Also, if you are looking to hire or be hired, Mark Schmeizl can help you find your perfect match. Contact Mark today to get started.

They both mark critical moments in humanity’s centuries-long quest to control physiology—and they bookend In this exclusive foundational-level lecture, Dr. Dr. Kenakin also celebrates the giants on whose shoulders we stand—A.J.

Join our upcoming Dr. GPCR University hands-on workshop with Dr.  The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Dr. Also, Mark Schmeizl can help you find your perfect match if you want to hire or be hired. Contact Mark today to get started.

GPCR University Today marks the final day of the Dr. Dr. GPCR Podcast We have thrilling news—Episode 153 of the Dr. GPCR Podcast featuring Dr. Dr. GPCR Matchmaking Read Mark's job spotlight article for a Principal Scientist in In Vitro Pharmacology Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology

Norton Cheng and Dr. Dr. Robert J Lefkowitz and team's study 'GPCR signal transduction: β-arrestin activates ERK MAPK.' Dr. Thomas P. Our confirmed speakers are Dr. Xavier Leroy, Dr. Brian Arey, and Dr. J. Silvio Gutkind. You can find more information about them on the Live Talks page and mark your calendar HERE.

Howard Rockman, and Dr.  GPCR Symposia Mark your calendars! Dr. GPCR University Great News! The Dr. Mark your calendar; we’re planning a workshop for May 2024 with Dr. Sam Hoare as our instructor. Dr.

Confirmed speakers include Drs.  Dr. GPCR University Last week marked the beginning of our first Dr.GPCR University course, 'Applying Pharmacology to Drug Discovery, led by Dr. Dr.

Isabella Russell, Drs. GPCR Symposia Mark your calendars! Dr. GPCR University Today marks the conclusion of the Dr.GPCR University course, ‘Applying Pharmacology to April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join Dr. GPCR Founder Dr.

This week's highlight includes congrats to: Dr. Levitz for their work on Emerging modes of regulation of neuromodulatory G protein-coupled receptors Dr GPCR University We are thrilled to announce that Dr. Stay tuned for more details, and mark your calendars for registration opening in July 2024. Dr. GPCR Podcast Tune into the 156th episode of the Dr. GPCR Podcast, featuring Dr.

This week's highlight includes congrats to Edda Matthees, Drs.  on GRK specificity and Gβγ dependency determines the potential of a GPCR for arrestin-biased agonism Dr CXV: The Class F of G Protein-Coupled Receptors Yusman Manchanda, Dr. We're thrilled to announce the dates for our upcoming courses led by the renowned Dr. Mark your calendars because registration opens on July 18, 2024!

Additionally, we are having a Panel Discussion on Publishing in Academia with Drs. Don't miss out, and mark your calendar! Dr. Gain invaluable skills in data analysis under Dr. Hoare's expert guidance. Dr. Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. Dr.

This week's highlight: Thank you to Dr. Let Mark Schmeizl, our Chief Matchmaker help. Contact him by filling out this form. Our November Dr. GPCR Newsletter is now available. This month's video newsletter features Dr. Don't miss the upcoming episodes of Dr.GPCR Podcast featuring Dr. Neil Grimsey and Dr. July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs - Contact Mark

Alexander Ball and Dr. Chia-Yi Lin, began. A word that admits what it doesn’t know Much of that trust problem, Dr. Dr. Dr. Lin arrived from a different door. Listen to the full conversation with Dr. Ball and Dr. Lin Watch the webinar recording with Dr. Ball

This week's highlight includes congrats to: Drs. Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. GPCR University We're thrilled to announce that Dr. Terry Kenakin will lead two brand-new, back-to-back courses tailored for the Dr. Mark your calendars for September and October 2024, and stay tuned for registration details coming this

Dr. Congrats to Dr. Mark your calendars for the following events: September 22- TOMORROW: Attend this Friday's Dr. GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Oliver Hartley, Dr. Pierre Eftekhari, Dr. Lauren Slosky, Dr. Christel Menet, Dr. Ben Myers and Dr.

It's spring break at Dr. Learn more about Live Masterclasses ➤ Partner Webinars Eurofins DiscoverX (Dr. GeneTex (Dr. Alex Ball)  — A reagent gap that holds back the biology. Details coming soon. Next Week in Boston The Dr. GPCR community gathers in person next week. Come find us ➤ About Dr. GPCR Dr. GPCR is the intelligence and community for GPCR scientists.

Dr. Kenakin is unequivocal: do not use them. Dr. Dr. Why Terry’s Corner Weekly pharmacology sessions with Dr. This orthosteric binding lesson closes out the year—marking 30 courses released  and 3 live AMAs hosted

Join Dr. Evan O'Brien, PhD, Johns Hopkins University Dr. Dr. Terry Kenakin, UNC and Head Instructor at Terry's Corner Dr. As Dr. Why Dr. GPCR Is in This Conversation At Dr.

Dr. Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Confirmed speakers include Drs. Dr. GPCR University This week marks the beginning of our first Dr.GPCR University course, 'Applying Pharmacology Dr.

Mark your calendars and get your ticket today! The Dr. GPCR Virtual Cafe is back! Our first guest speaker is none other than Dr. Ben Myers! https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

In Episode 168 of the Dr. GPCR Podcast, Dr. And that mindset is precisely what makes their new partnership with Dr. GPCR so powerful. ” — Dr. That’s the mission. ” — Dr. Maria Majellaro Now, as official partners of the Dr. Keyword Cloud:   GPCR data platform , fluorescent ligands , assay development , GPCR research community , Dr

Plus, check out the latest Dr. GPCR tools and key moves in the biotech world. Dr. Become a Dr. GPCR Ambassador - Share & refer with Dr. GPCR.   Join the Affiliate Program     Your Shortcut to Dr. The Dr. Best wishes, The Dr. GPCR Team

Congratulations to Dr. Don't forget to mark your calendars for July 21st, as the upcoming Dr. Be sure to subscribe to Dr. GPCR Newsletter for updates! Industry News Dr. Associate Director / Director, Clinical Operations Professor in Cardiovascular Pharmacology Explore Dr

Dr. Maria Majellaro’s story, shared in Episode 168 of the Dr. ” — Dr. Maria Majellaro Maria didn’t always know she’d end up in a startup. ” — Dr. With the new  Dr. . 👉 Explore Celtarys’ tools and partnership with Dr.